Click here For Free Sample Report @ [URL]https://www.mrrse.com/sample/2751[/URL]

Kidney diseases are one of the leading causes of death worldwide. The incidence of chronic kidney diseases is rapidly rising especially in the elderly population due to increase in life expectancy of general population and improvements in medical management services. However, diabetes and hypertension remain the leading cause of renal diseases. Biomarkers are measurable indicators reflecting physiological and pharmacological progression of disease state. Recent advances in molecular biology have resulted in the development of novel biomarkers for the renal function. Extensive R&D by biomarker manufacturers has led to identification of novel renal biomarkers to deliver better diagnostic accuracy and improve patient outcomes.

Market forecast

Revenue from the global renal biomarker market is projected to register a CAGR of 7.0% during the forecast period (2016 – 2026) and reach a market valuation of US$ 1,770.3 Mn by the end of 2026.

Browse Full Report With TOC @ [URL]https://www.mrrse.com/renal-biomarker-market[/URL]

Market segmentation

By Biomarker Type By Diagnostic Technique By End User By Region

·         Functional Biomarker

·         Serum Creatinine

·         Serum Cystatin C

·         Urine Albumin

·         Up-Regulated Proteins

·         Neutrophil gelatinase-associated lipocalin

·         Kidney injury molecule 1

·         Interleukin 18

·         Others

·         Enzyme Linked Immunosorbent Assay

·         Particle-Enhanced Turbidimetric Immunoassay

·         Colorimetric Assay

·         Chemiluminescent Enzyme Immunoassay

·         Liquid Chromatography-Mass Spectrometry

·         Diagnostic Labs

·         Outpatient Clinics

·         Research Centres

·         Hospitals

·         North America

·         Latin America

·         Western Europe

·         Eastern Europe

·         Asia Pacific Excluding Japan (APEJ)

·         Japan

·         Middle East & Africa (MEA)

Check Discount @ [URL]https://www.mrrse.com/checkdiscount/2751[/URL]

Enzyme Linked Immunosorbent Assay diagnostic technique segment estimated to hold the highest market share throughout the forecast period

The Enzyme Linked Immunosorbent Assay segment is anticipated to register a CAGR of 8.1% over the forecast period and is expected to register high Y-o-Y growth rates from 2016 to 2026. The Particle-Enhanced Turbidimetric Immunoassay segment is estimated to be the second largest segment in terms of value, holding a market value share of 21.0% by 2016 end.

Make An Enquiry @ [URL]https://www.mrrse.com/enquiry/2751[/URL]